{"id":7147,"date":"2025-04-28T11:05:37","date_gmt":"2025-04-28T09:05:37","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7147"},"modified":"2025-04-28T21:17:29","modified_gmt":"2025-04-28T19:17:29","slug":"notch1-mutation-and-survival-analysis-of-tislelizumab-in-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-a-biomarker-analysis-from-the-randomized-phase-iii-rationale-302-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/notch1-mutation-and-survival-analysis-of-tislelizumab-in-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-a-biomarker-analysis-from-the-randomized-phase-iii-rationale-302-trial\/","title":{"rendered":"NOTCH1 mutation and survival analysis of tislelizumab in advanced or metastatic esophageal squamous cell carcinoma: a biomarker analysis from the randomized, phase III, RATIONALE-302 trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-7147","publication","type-publication","status-publish","hentry","disease_state-esophageal-squamous-cell-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7147"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}